Clinical trials: Patients With Schizophrenia
Schizophrenia, Quality of Life
Milestones of Adjustment Post-Psychosis
This nested design clinical outcome study of psychiatric case manager education on disease state, psychopharmacology of schizophrenia, relapse, motivational interviewing, and the process of psychological adjustment post-psychosis…
- Conditions
- Schizophrenia, Quality of Life, Adjustment, Psychological, Medication Adherence
- Trial name
- MAPP (NCT01192594)
- Testing
- Training in all modules including MAPP Recovery Model, Training in all modules except MAPP Recovery Model
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia
Clinical Trial of Tolcapone for Cognition in Schizophrenia
This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the…
- Trial name
- NCT00044083
- Testing
- Tolcapone
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
The purpose of this study is to evaluate the effect of single doses of NSA-789 on the P50 component of the auditory evoked potentials and to assess the safety, tolerability and the concentration of NSA-789 in the blood, in…
- Trial name
- NCT00781794
- Testing
- NSA-789 at 2 different doses
- Where
- 3 sites in United States, France
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Hallucinations
Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations
This study will evaluate the long-term effects of repetitive transcranial magnetic stimulation (rTMS) in patients with auditory hallucinations.
- Trial name
- NCT00042159
- Testing
- repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Refractory Schizophrenia
Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia
Primary Objective: Efficacy of Occupational Therapy (OT) based Occupational Goal Intervention (OGI) in improving executive functions in patients with refractory schizophrenia as measured by the BADS.
- Trial name
- OTSchizo (NCT01879956)
- Testing
- Craft Activities, OGI Method
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Schizoaffective Disorder, Schizophrenia
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another…
- Trial name
- NCT00378183
- Testing
- risperidone
- Volunteers
- 120 people
- Sponsor
- Janssen, LP
Dementia, Alzheimer Disease
Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease
- Conditions
- Dementia, Alzheimer Disease, Mental Disorders
- Trial name
- NCT00034762
- Testing
- risperidone
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?
The investigators want to try to improve information processing in schizophrenic patients via pharmacological intervention. The hypothesis is that decreased noradrenergic activity will normalize information processing (PPI, P50…
- Trial name
- NCT00206986
- Testing
- clonidine
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj
Psychosis
An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)
This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication.
- Trial name
- NCT00878462
- Testing
- Asenapine WHITE raspberry flavor (Treatment A), Asenapine RED raspberry flavor (Treatment B), Asenapine WHITE UNFLAVORED (Treatment C)
- Volunteers
- 174 people
- Sponsor
- Organon and Co
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Schizophrenia, Schizophreniform Disorders
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early Schizophrenia
This study aims to test the hypothesis that addition of Individual Placement and Support (IPS) and/or Cognitive Remediation Therapy (CRT) in addition to treatment as usual in patients with early psychosis will be feasible and…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychosis
- Trial name
- NCT03974620
- Testing
- Individual Placement and Support, Cognitive Remediation Therapy
- Volunteers
- 120 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia
A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics
The primary purpose of the study is to compare the rate of hospitalization associated with psychotic relapse in participants with schizophrenia treated one year before with oral antipsychotics and one year after with long acting…
- Trial name
- REALAI (NCT02712463)
- Where
- 11 sites in Brazil, Mexico
- Volunteers
- 310 people
- Sponsor
- Janssen-Cilag Ltd.
Inhibition (Psychology), Schizophrenia
Prepulse Inhibition (PPI) of Startle Reflex in Schizophrenia Patients Related to Type of Treatment and Illness Duration
PPI is an objective measure to assess pre-attentive processes that have already been tested before in the case of schizophrenia.
- Conditions
- Inhibition (Psychology), Schizophrenia, Medication Adherence
- Trial name
- NCT02484521
- Testing
- PPI monitoring device protocol, Questionnaires
- Where
- Israel
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Schizophrenia
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.
- Trial name
- CRESSOB (NCT00584519)
- Testing
- non-interventional
- Volunteers
- 430 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia Negative Type
tDCS Combined With rTMS for Negative Symptoms of Schizophrenia
Despite major advances in the field of psychopharmacology in recent years, the majority of treated schizophrenia patients retain disabling symptoms, most commonly a variety of negative symptoms.
- Trial name
- NIBSNeS (NCT05695144)
- Testing
- tDCS active stimulation combined with rTMS active stimulation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Anding Hospital
Schizophrenia
A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia
In this study, we assessed the therapeutic effects and safety of left dorsolateral prefrontal cortex (DLPFC) high-frequency repetitive transcranial magnetic stimulation (rTMS) on negative symptoms of schizophrenia.
- Trial name
- NCT03273439
- Testing
- repetitive TMS
- Volunteers
- 47 people
- Sponsor
- Suzhou Psychiatric Hospital
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
The objective of the study is to determine whether Panax Ginseng with multiple interactions with key components of brain signaling pathway, can augment the effects of antipsychotics in Schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tardive Dyskinesia, Insulin Resistance
- Trial name
- NCT00401089
- Testing
- Panax Ginseng
- Where
- 4 sites in Canada, United Kingdom
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia, Psychotic Disorders
Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention
This is a randomized pilot study of an intervention based on principles of Cognitive Behavioral Therapy (CBT). This intervention is the Health Dialogue Intervention (HDI) and will be compared to a traditional medical model of…
- Trial name
- NCT00980252
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Illinois Chicago
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine add-on to risperidon treatment for the prevention of cognitive dysfunction and negative symptomatology in patients with acute schizophrenia.
- Trial name
- NCT00148590
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- M. Schaefer, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.